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RESEARCH ARTICLE Open Access
Evaluation of a field-deployable reverse
transcription-insulated isothermal PCR for
rapid and sensitive on-site detection of
Zika virus
Mariano Carossino1, Yanqiu Li1, Pei-Yu A. Lee2, Chuan-Fu Tsai2, Pin-Hsing Chou2, Dennis Williams3,
Ashley Skillman1, R. Frank Cook1, Grayson Brown4, Hsiao-Fen G. Chang2, Hwa-Tang T. Wang2
and Udeni B. R. Balasuriya1*
Abstract
Background: The recent emergence of Zika virus (ZIKV) in Brazil and its precipitous expansion throughout the Americas
has highlighted the urgent need for a rapid and reliable on-site diagnostic assay suitable for viral detection. Such point-of-
need (PON), low-cost diagnostics are essential for ZIKV control in vulnerable areas with limited resources.
Methods: We developed and evaluated a ZIKV-specific field-deployable RT-iiPCR reagent set targeting the E gene for
rapid detection of ZIKV in ZIKV-spiked human and mosquito specimens, and compared its performance to the Center
for Disease Control and Prevention (CDC) and Pan American Health Organization (PAHO) RT-qPCR assays targeting the
E and NS2B genes, respectively.
Results: These assays demonstrated exclusive specificity for ZIKV (African and Asian lineages), had limits of detection
ranging from 10 to 100 in vitro transcribed RNA copies/μl and detection endpoints at 10 plaque forming units/ml of
infectious tissue culture fluid. Analysis of human whole blood, plasma, serum, semen, urine, and mosquito pool samples
spiked with ZIKV showed an agreement of 90% (k = 0.80), 92% (k = 0.82), 95% (k = 0.86), 92% (k = 0.81), 90% (k = 0.79),
and 100% (k = 1), respectively, between the RT-iiPCR assay and composite results from the reference RT-qPCR assays.
Overall, the concurrence between the ZIKV RT-iiPCR and the reference RT-qPCR assays was 92% (k = 0.83).
Conclusions: The ZIKV RT-iiPCR has a performance comparable to the reference CDC and PAHO RT-qPCR assays but
provides much faster results (~1.5 h) with a field-deployable system that can be utilized as a PON diagnostic with the
potential to significantly improve the quality of the health care system in vulnerable areas.
Keywords: Zika virus, Insulated isothermal PCR, iiPCR, POCKIT, Point-of-need assay
Background
Zika virus (ZIKV) is a mosquito-borne flavivirus first
isolated in 1947 from a febrile rhesus macaque monkey
in the Zika Forest of Uganda and subsequently identified
in infected Aedes africanus mosquitoes [1, 2]. Human
infection was first reported in Nigeria in 1954 [3], how-
ever ZIKV remained in relative obscurity for nearly
60 years until a change in its infection pattern was ob-
served with the occurrence of the first major outbreak in
Yap (Federated States of Micronesia) where approxi-
mately 74% of the population were infected and 18% of
the infected people developed symptomatic disease [4],
typically characterized by an acute, mild febrile illness of
short duration. Since then, ZIKV has spread throughout
the Pacific, and serosurveillance studies suggest that
ZIKV infection is widespread throughout Africa, Asia,
and Oceania [4–7]. In March 2015, ZIKV was first iden-
tified in the Americas associated with an extensive out-
break of exanthematous illness in Bahia, Brazil with an
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estimate of 1.3 million suspected cases by December
2015 [8–11]. The virus precipitously spread throughout
the Americas and has now been reported in at least 33
countries including Puerto Rico, US Virgin Islands, and
the continental US [5, 6, 12, 13].
ZIKV belongs to the family Flaviviridae, genus Flavivirus,
and it is closely related to other mosquito-borne flavi-
viruses such as dengue (DENV), West Nile (WNV),
and Japanese encephalitis viruses (JEV) [14, 15]. ZIKV
has a positive-sense, single stranded RNA (+ ssRNA)
genome of approximately 11 kb in length and a single
open reading frame (ORF) flanked by two untranslated
regions (UTRs) at both the 5′ and 3′ termini. The sin-
gle ORF encodes for a polyprotein that, upon cleavage,
gives rise to 3 structural (capsid [C], precursor of mem-
brane [prM], and envelope [E] proteins) and 7 non-
structural proteins (NS1, NS2A, NS2B, NS3, NS4A,
NS4B, and NS5) [14–18]. ZIKV strains can be phylo-
genetically grouped into two distinct phylogenetic line-
ages (African and Asian lineages) [5, 17, 19, 20].
Similarly to other flaviviruses, ZIKV is primarily trans-
mitted by Aedes species of mosquitoes, including the
urban and suburban mosquito species A. aegypti and A.
albopictus, also implicated in the transmission of
DENV and alphaviruses such as Chikungunya virus
(CHIKV) [18, 21–25]. Even though urban and suburban
transmission cycles involve human-mosquito-human
transmission, the sylvatic transmission cycle apparently
involves non-human primates as the main viral reser-
voir [5]. In addition, ZIKV can be transmitted from the
mother to the developing fetus during pregnancy or to
the infant during the peripartum [26]. Most import-
antly, the virus can be transmitted during sexual inter-
course via semen or vaginal secretions [27–31]. Also,
ZIKV can be potentially transmitted by blood transfu-
sions [32–36], and transmission through transfusion of
a platelet concentrate has been recently reported in
Brazil [36].
Although the vast majority of infected individuals
(approximately 80%) remain asymptomatic, ZIKV can
cause a wide range of clinical manifestations ranging
from a mild, acute febrile illness to severe neurologic
disease (i.e. Guillain-Barré syndrome), and devastating
congenital anomalies including microcephaly, ocular
malformations, and other neurologic defects [5, 6,
37–43]. However, in adult individuals where clinical
manifestations do occur they are usually mild, self-
limiting, and non-specific associated with an acute fe-
brile illness characterized by low-grade (~38 °C) and
short-term (2–7 days) fever, fatigue, rash, arthralgia, my-
algia, headache, and conjunctivitis. These clinical signs
are indistinguishable from those induced by many other
flaviviral or alphaviral infections. Hence, laboratory diag-
nosis of ZIKV is mandatory to confirm the clinical
diagnosis [5, 43, 44]. Therefore, the availability of rapid,
reliable, and relatively low cost diagnostic tools is of
utmost importance for ZIKV control and management.
Currently, clinical diagnosis of ZIKV infection relies on
serological assays for the detection of antibodies (including
rapid lateral-flow immunochromatographic assays, IgM
capture enzyme-linked immunosorbent assay [MAC-
ELISA], and plaque reduction neutralization test [PRNT])
and molecular-based assays for the detection of viral nu-
cleic acids (conventional or quantitative, real-time reverse
transcription polymerase chain reaction [RT-qPCR])
[43–45]. Serological assays do not offer a suitable specifi-
city due to the extensive antibody cross-reactivity with
other flaviviruses [43–45]. In contrast, molecular-based as-
says for detection of ZIKV RNA (e.g. RT-qPCR) are high
throughput, sensitive, and highly specific. Several conven-
tional and RT-qPCR assays have been described [43–51].
To date, there are two ZIKV RT-qPCR assays validated by
the Center for Disease Control and Prevention (CDC;
Atlanta, GA, USA) which target the prM and E genes [17],
and an NS2B-specific RT-qPCR assay recently developed
by the Pan American Health Organization (PAHO) in re-
sponse to the ZIKV outbreak in South America which in-
tends to replace the CDC-validated ZIKV prM RT-qPCR
assay of lower sensitivity [43]. However, the use of
RT-qPCR assays as diagnostic tests requires centralized la-
boratory facilities, trained personnel, expensive equip-
ment, and extended turnaround times associated with
sample transportation over large distances. Consequently,
RT-qPCR assays are not suitable for use within clinical set-
tings in rural areas or may not be available in areas with
poor resources including developing countries where
ZIKV is spreading at an accelerated rate. Therefore, the
socio-economic gap implies that a significant number of
suspected cases do not have access to appropriate testing.
For these reasons, point-of-need (PON) molecular detec-
tion tools for easy, rapid, reliable, inexpensive, and on-site
ZIKV testing can not only significantly improve the quality
of the health care system in vulnerable areas, but also en-
sure rapid testing in blood banks and provide enhanced
field surveillance of ZIKV transmission with an overall im-
pact of major significance on public health. To date, only
three potential PON, molecular-based assays to detect
ZIKV RNA have been developed, although not extensively
evaluated on target diagnostic specimens [52–54].
Recently, a fluorescent probe hydrolysis-based insu-
lated isothermal PCR (iiPCR) for amplification and de-
tection of nucleic acids has been described [55] for a
number of important pathogens including DENV,
Middle East respiratory syndrome coronavirus (MERS-
CoV), and Plasmodium spp. in human specimens
[56–58]. The iiPCR is highly sensitive and specific for
the detection of both DNA and RNA not only from hu-
man, but also various animal pathogens [59–70]. The
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PCR reaction (denaturation, annealing, and extension) is
accomplished in a capillary vessel (R-tube™; GeneReach
USA, Lexington, MA, USA) heated through the bottom
end of the tube where, based on the Rayleigh-Bénard
convection principle, the fluids cycle through temperature
gradients. The results are ready in a short time (~ 1.5 h)
within a field-deployable device (POCKIT™ Nucleic Acid
Analyzer, GeneReach USA). Integration of the hydrolysis
probe technology and an optical detection module allows
automatic detection and interpretation of iiPCR results in
the form of “positive” or “negative” readouts in a relatively
low-cost device [55] (Fig. 1).
In this study, we developed and evaluated a PON one-
step RT-iiPCR reagent set targeting the E gene for the
detection of ZIKV RNA from spiked-in specimens in a
field-deployable system (POCKIT™). The analytical sensi-
tivity and specificity were extensively analyzed and
compared to the reference CDC (prM and E genes) and
PAHO (NS2B gene) singleplex RT-qPCR assays. Subse-
quently, the performance of the three assays was com-
pared using ZIKV-spiked specimens (including whole
blood, plasma, serum, semen, and urine) and homoge-
nized mosquito pools.
Methods
Cells, viruses, and viral RNA
Vero cells (ATCC® CCL-81™) were maintained in Eagle’s
minimum essential medium (EMEM, Mediatech, Inc.,
Manassas, VA) supplemented with 10% fetal bovine
serum (Atlanta Biologicals, Flowery Branch, GA), 2 mM
L-glutamine (Gibco®, Carlsbad, CA), and penicillin and
streptomycin (100 U/ml and 100 μg/ml, respectively;
Gibco®) at 37 °C in 5% CO2 atmosphere. The mosquito
cell lines C6/36 (A. albopictus [ATCC® CRL-1660™]) and
AP-61 (A. pseudoscutellaris) were kindly provided by Dr.
Jason Velez (CDC, Atlanta, GA). C6/36 were maintained
in 1X Dulbecco’s modified minimum essential medium
(DMEM, Gibco®) supplemented with 7.5% sodium
bicarbonate (Gibco®), 10% fetal bovine serum, 1X
non-essential amino acids (Gibco®), and 1 mM sodium
pyruvate (Gibco®) at 30 °C in 5% CO2 atmosphere.
AP-61 were maintained in 1X Leibovitz’s L-15 medium
(Gibco®) supplemented with 2 mM L-glutamine, 10%
fetal bovine serum, and 7.5% tryptone phosphate broth
(Sigma-Aldrich, St. Louis, MO) at 30 °C in 5% CO2
atmosphere.
Tissue culture fluid (TCF) derived from Vero cells in-
fected with ZIKV PRVABC59 (ATCC® VR-1843™), FLR
(ATCC® VR-1844™), and MR766 (ATCC® VR-1838™)
strains were used for analytical sensitivity and specificity
evaluation of ZIKV-specific RT-qPCR and RT-iiPCR as-
says. Briefly, confluent monolayers of Vero cells were in-
oculated with a 1/10 dilution of ZIKV PRVABC59, FLR,
and MR 766 strains in a minimal volume of maintenance
media without fetal bovine serum. After 1 h adsorption
at 37 °C, monolayers were overlaid with complete
EMEM and incubated at 37 °C and 5% CO2 until 100%
cytopathic effect was observed (72 h post infection).
Infected flasks were frozen/thawed, clarified by centrifu-
gation at 1500 X g for 15 min at 4 °C, aliquoted, and
stored at −80 °C. Mosquito cell lines, C6/36 and AP-61,
were infected in a similar fashion. Viral stocks were sub-
sequently titrated in confluent 6-well plates of Vero
cells. Briefly, serial ten-fold dilutions (10−1 – 10−12) of
virus stocks were prepared in 1X MEM (Mediatech,
Inc.) and 200 μl of each dilution were added in duplicate
wells. After 1 h adsorption at 37 °C and 5% CO2, in-
fected monolayers were overlaid with complete EMEM
supplemented with 0.75% carboxymethylcellulose
(Sigma-Aldrich, St. Louis, MO) and incubated for 96 h.
Fig. 1 POCKIT™ system workflow for point-of-need detection of Zika virus RNA. This system includes a compact automatic nucleic acid extraction
device (taco™ mini) and a portable PCR device (POCKIT™). After sample collection, nucleic acids are extracted using a preloaded extraction plate in
approximately 30 min and, subsequently, the lyophilized RT-iiPCR reaction is reconstituted and nucleic acids are added and tested. TaqMan® probe
hydrolysis-based amplification signals are detected and automatically processed, providing qualitative results on the display screen after 60 min
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Monolayers were stained with a 1% crystal violet solu-
tion, and viral titers expressed as plaque forming units
per ml (PFU/ml) of TCF.
Genomic RNA from diverse ZIKV strains and Dengue
virus (DENV) serotypes 1–4 (Table 1) were obtained
from BEI Resources (Manassas, VA). Yellow fever virus
(YFV), WNV, and CHIKV RNA (Table 1) were obtained
from the European Virus Archive (EVAg, Marseille,
France).
Human blood, urine and semen samples and mosquitoes
Unused whole blood (6 ml tubes containing EDTA) and
serum (6 ml clot tubes) from 20 healthy donors were ob-
tained through the Kentucky Blood Center, Beaumont
Centre Circle, Lexington, KY to be used in this study.
Archived urine samples from healthy volunteers were
obtained from the BioBank, Center for Clinical and
Translational Science, Chandler Medical Center, College
of Medicine, University of Kentucky, Lexington,
Kentucky. All the donors have provided informed con-
sent at the time of sample submission and the specimens
were coded and individual identifiers were permanently
removed from specimens. Human semen samples were
obtained from a commercial source (Lee Biosolutions,
Inc., Maryland Heights, MO, USA). Dead A. albopictus
mosquitoes were obtained from the Department of
Entomology, College of Agriculture, Food and Environ-
ment, University of Kentucky, Lexignton, Kentucky.
ZIKV-spiked human specimens (whole blood, plasma,
serum, semen, and urine)
Whole blood and serum specimens from each donor
were separated into six aliquots and spiked with ZIKV
PRVABC59 strain (1 × 107 PFU/ml of TCF) to yield dif-
ferent viral titers (106, 103, 102, 10, and 1 PFU/ml) of
whole blood or serum. One aliquot of both whole blood
and serum from each donor was inoculated with an
equivalent volume of uninfected EMEM as mock-spiked
control. Overall, a total of 20 specimens for each viral
concentration were generated (20 donors x [five different
viral concentrations plus one mock-spiked control] = 120
whole blood/serum specimens). An aliquot from each
spiked whole blood specimen (n = 120) was stored at
−80 °C until nucleic acid extraction, while the remaining
was centrifuged at 1000 X g for 10 min at 4 °C for
plasma separation (n = 120) and stored at −80 °C until
nucleic acid extraction. Spiked serum samples (n = 120)
were stored at −80 °C until nucleic acid extraction.
Similarly, a total of 20 archived urine samples (stored at
−80 °C) were obtained from volunteer donors (males/
females). Urine samples (n = 120) were separated and
spiked with different concentrations of ZIKV
PRVABC59 strain as described above and stored at
−80 °C until nucleic acid extraction.
In addition, a total of 4 pooled whole semen samples
(1 ml each, 3 human donors per pool, 12 total human
donors) from healthy, certified infectious disease-free
male donors were purchased from Lee Biosolutions, Inc.
Each pool was separated into 6 aliquots and spiked with
different concentrations of ZIKV PRVABC59 strain to
reach viral titers of 106, 103, 102, 10, and 1 PFU/ml of
whole semen as explained above. One aliquot was inocu-
lated with an equivalent volume of uninfected EMEM as
mock-spiked control. Spiked aliquots were stored at
−80 °C until nucleic acid extraction.
ZIKV-spiked mosquito pools
A total of 105 A. albopictus mosquitoes were divided into
7 pools (15 mosquitoes per pool). One ml of mosquito di-
luent (1X DMEM supplemented with 10% fetal bovine
serum, 0.05 mg/ml gentamicin sulphate [Mediatech, Inc.],
100 U/ml and 100 μg/ml of penicillin and streptomycin,
and 5 μg/ml amphotericin B (Gibco®) containing various
concentrations of ZIKV PRVABC59 strain (106, 104, 103,
102, 10, 1 PFU/ml, respectively which provided concentra-
tions ranging from 6 × 104 − 0.06 PFU/mosquito) were
used to spike each mosquito pool. One mosquito pool was
spiked with 1 ml of mosquito diluent as mock-spiked con-
trol. Subsequently, mosquito pools were completely ho-
mogenized using an Omni TH homogenizer (Omni, Inc.,
Kennesaw, GA) and disposable tips, and centrifuged at
1500 X g for 20 min at 4 °C. The clarified homogenate
was stored at −80 °C until nucleic acid extraction.
Table 1 Viruses utilized to assess the analytical specificity of the
new point-of-need ZIKV RT-iiPCR assay
Virus strain Place and year of isolation Source
ZIKV PRVABC59 Puerto Rico, 2015 ATCC®
ZIKV FLR Colombia, 2015 ATCC®
ZIKV MR 766 Uganda, 1947 ATCC®
ZIKV IB H 30656 Nigeria, 1968 BEI
ZIKV H/PAN/2015/CDC-259359 Panama, 2015 BEI
ZIKV H/PAN/2015/CDC-259249 Panama, 2015 BEI
ZIKV H/PAN/2015/CDC-259364 Panama, 2015 BEI
DENV serotype 1, Hawaii Hawaii, 1944 BEI
DENV serotype 2, New Guinea C New Guinea, 1944 BEI
DENV serotype 3, Philippines/H87/
1956
Republic of the Philippines,
1956
BEI
DENV serotype 4, H241 Republic of the Philippines,
1956
BEI
YFV 17D N/A EVAg
WNV NY99 New York, 1999 EVAg
CHIKV H20235/STMARTIN/2013 St. Martin, 2013 EVAg
ZIKV Zika virus, DENV dengue virus, YFV yellow fever virus, WNV West Nile
virus, CHIKV Chikungunya virus, N/A not applicable, ATCC® American Type
Culture Collection, BEI BEI Resources, NIAID, NIH, EVAg European Virus Archive
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Nucleic acid extraction
Nucleic acids from TCF, spiked human specimens
(whole blood, plasma, serum, semen, and urine), and
spiked mosquito pools were extracted using an
automated magnetic bead-based extraction system
(taco™ mini, GeneReach USA) as previously described
[56, 66]. Briefly, 200 μl of TCF, spiked whole blood,
plasma, serum, urine, or supernatant derived from mos-
quito pools were added into the first well of a taco™
Preloaded DNA/RNA Extraction plate (GeneReach
USA) containing lysis buffer and subjected to the extrac-
tion steps as described in the manufacturer’s user man-
ual. Elution was performed with 200 μl of Elution buffer.
Due to sample limitations, 100 μl of spiked semen sam-
ples were used and nucleic acids were eluted with 100 μl
of Elution buffer. All nucleic acids were stored at −80 °C
for future use.
Synthesis of target genes and in vitro transcribed RNA
preparation
ZIKV-specific in vitro transcribed (IVT) RNA was syn-
thesized in order to determine the analytical sensitivity
of the ZIKV-specific RT-iiPCR and compared with the
ZIKV-specific CDC (prM and E) and PAHO (NS2B)
RT-qPCR assays. For this purpose, a 614 nt insert con-
taining the targeted regions (prM [nt position 900-1000],
E [nt position 1084–1364], NS2B [nt position
4500-4610] and NS5 gene [nt position 9340–9460]
genes) derived from ZIKV PRVABC59 strain (GenBank
Accession number KX087101.2) were chemically synthe-
sized and cloned into the pGEM®-3Z vector (Promega,
Madison, WI) downstream of the T7 promoter (pZIKV-
MENS2B5) by a commercial company (GeneArt™ Gene
Synthesis, ThermoFisher Scientific, Regensburg,
Germany). Subsequently, E. coli K12 DH10B™ T1R were
transformed with the construct. Transformed bacteria
were cultured overnight at 37 °C with shaking
(270 rpm). Plasmid DNA was purified using QIAprep
Spin Miniprep kit (Qiagen, Valencia, CA) following the
manufacturer’s instructions and screened by restriction
digestion using the unique EcoRI, BamHI, and HindIII
restriction sites within and flanking the insert. Sequence
authenticity was confirmed by Sanger sequencing using
T7 and SP6 promoter-specific primers. Plasmid DNA
(1 μg) was linearized using HindIII, purified using the
High Pure PCR Product Purification kit (Roche,
Indianapolis, IN) as instructed, and 0.5 μg of plasmid
DNA was used for in vitro transcription of the ZIKV
MENS2B5 insert using the Megascript® T7 Transcription
kit (ThermoFisher Scientific, Waltham, MA) following the
manufacturer’s recommendations. Residual plasmid DNA
was removed by digestion with TURBO™ DNase
(ThermoFisher Scientific) for 15 min at 37 °C. The IVT
RNA product was analyzed by agarose gel electrophoresis,
subjected to a clean-up procedure using the MEGAclear™
Transcription Clean-Up kit (ThermoFisher Scientific), and
quantified using a NanoDrop 2000 spectrophotometer
(ThermoFisher Scientific). The ZIKV MENS2B5 IVT
RNA was stored at −80 °C until used. The number of
ZIKV IVT RNA molecules per microliter (copies/μl) was
calculated according to the following formula:
Number of IVT RNA molecules=μL
¼ Avogadro
0
s number 6:022 1023ð Þ  IVT RNA concentration g=μLð Þ
IVT RNA molecular weight gð Þ
The concentration of ZIKV IVT RNA was adjusted to
107 copies/μl using nuclease-free water containing 40 ng/
μl of Ambion® Yeast tRNA (ThermoFisher Scientific), and
serially ten-fold diluted (107 − 0.1 IVT RNA copies/μl)
using nuclease-free water containing Ambion® Yeast
tRNA.
ZIKV-specific TaqMan® real-time RT-PCR assays
The CDC-validated ZIKV-specific TaqMan® RT-qPCR as-
says targeting prM and E genes along with the PAHO
ZIKV-specific TaqMan® RT-qPCR assay targeting NS2B
gene were utilized as previously described. Primer and
probe sequences as well as fluorescent dyes and quenchers
used are shown in Table 2. The reaction was set up using
the QuantiTect Probe RT-PCR kit (Qiagen) following the
manufacturer’s recommendations. Briefly, the 25 μl reac-
tion contained 12.5 μl of 2X QuantiTect Probe RT-PCR
Master Mix with ROX, 0.25 μl QuantiTect RT Mix,
200 nM TaqMan® fluorogenic probe, 500 nM each primer,
and 5 μl of template RNA. Reverse transcription and amp-
lification were carried out in an ABI 7500 Fast Real-time
PCR System (Applied Biosystems®, Life Technologies,
Grand Island, NY). The program included 30 min at 50 °C
(reverse transcription step), 15 min at 95 °C (PCR initial
activation step), followed by 45 cycles at 94 °C for 15 s
(denaturation) and 60 °C for 1 min (combined annealing/
extension). Even though the analytical sensitivity and
specificity of all ZIKV-specific RT-qPCR assays (targeting
prM, E, and NS2B) were evaluated, only the ZIKV
RT-qPCR assays targeting E and NS2B were used to assess
their performance in ZIKV-spiked specimens and to com-
pare with the performance of the ZIKV RT-iiPCR reagent
set. Amplification with one of the two ZIKV RT-qPCR as-
says (E and NS2B) determined a sample as positive, with a
cutoff Ct value of ≤38.5 as described by Lanciotti, et al.
[17]. Samples with 38.5 < Ct value ≥45 were considered
inconclusive.
ZIKV-specific reverse-transcription insulated isothermal PCR
The ZIKV-specific RT-iiPCR (POCKIT™ Zika Virus
Reagent Set) assay was designed to target the E gene of
ZIKV (proprietary). The RT-iiPCR reaction conditions,
such as concentrations of primers and probe, Taq DNA
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polymerase, and reverse transcriptase, were tested sys-
tematically to obtain the highest sensitivity and specifi-
city. Following optimization of the RT-iiPCR assay
conditions, the reagents including primers and probe
were lyophilized (proprietary) and used in this study.
Briefly, after reconstituting the lyophilized pellet with 50
μl of Premix Buffer B (GeneReach USA), 5 μl of the
sample nucleic acid was added to the reaction. Subse-
quently, 50 μl of the final mixture was transferred into
an R-tube™ (GeneReach USA), sealed with a cap, spun
for 10 s in a cubee™ centrifuge (GeneReach USA), and
placed into a POCKIT™ device (GeneReach USA). The
default program, that included an RT step at 50 °C for
10 min and an iiPCR step at 95 °C for 30 min, com-
pleted in less than one hour. Signal-to-noise (S/N) ra-
tios, i.e. light signals collected after iiPCR/fluorescent
signals collected before iiPCR [65], were converted auto-
matically to “+”, “-”, or “?” according to the default S/N
thresholds by the built-in algorithm. The results were
shown on the display screen at the end of the program.
A “?” indicated that the results were ambiguous and the
sample should be tested again (Fig. 1).
Statistical analysis
Standard curves were performed using nucleic acids
prepared from a serial dilution series of both a
ZIKV-infected TCF stock (1 × 107 PFU/ml) and IVT
RNA (107 to 0.1 IVT RNA copies/μl). Pearson correl-
ation coefficients (R2) were used to assess curve fitness.
PCR amplification efficiencies (%) were calculated using
the following formula: E ¼ 10− 1slope−1
h i
 100 after
regression analysis. Limit of detection with 95% confi-
dence (LOD95%) was determined by statistical probit
analysis (a non-linear regression model) using the com-
mercial software SPSS 14.0 (SPSS Inc., Chicago, IL,
USA) for all assays (ZIKV prM, E, and NS2B RT-qPCR,
and ZIKV E RT-iiPCR). The performance of ZIKV RT-
iiPCR in spiked-in specimens was compared to the
combined use of E and NS2B RT-qPCR assays; the over-
all degree of agreement between the assays (combined
CDC E and PAHO NS2B RT-qPCR vs. RT-iiPCR) was
evaluated for the total number of specimens, and also by
sample type categories independently. Contingency ta-
bles (2 × 2) for ZIKV- and mock-spiked samples were
generated to estimate the relative sensitivity and specifi-
city of each assay per sample category, and compared
using the McNemar’s test for paired data. The level of
significance was set at 0.01.
Results
Comparison of the analytical sensitivity and specificity
of the ZIKV RT-iiPCR and reference CDC and PAHO
ZIKV RT-qPCR assays
(i).Analytical sensitivity. The analytical sensitivity of
the PON ZIKV RT-iiPCR was determined using a
(a) ten-fold dilution series (six replicates per dilu-
tion) of ZIKV IVT RNA (107 to 0.1 IVT RNA
copies/μl) containing the target sequence, and (b)
ten-fold serial dilutions (100–10−13) of nucleic acid
extracted from TCF derived from ZIKV PRVABC59-
infected Vero cells containing a viral titer of 107
PFU/ml. These samples were also used to determine
the analytical sensitivities of the CDC-validated prM
and E, and PAHO-validated NS2B ZIKV RT-qPCR
assays (Tables 3 and 4). Standard curves generated
for the three RT-qPCR assays using both a serial di-
lution of infectious TCF and IVT RNA demon-
strated perfect linearity (R2 > 0.99) and optimal
amplification efficiencies ranging between 97% and
105% (data not shown). For the ZIKV IVT RNA ser-
ial dilution, the RT-iiPCR showed 100%, 83%, 83%,
17%, and 0% detection rates for reaction mixtures
containing 1000; 100; 10; 1; and 0.1 IVT RNA cop-
ies/μl, respectively (Table 3), and a 100% detection
endpoint at 10 PFU/ml of infectious TCF
(PRVABC59 strain, Table 4). Probit analysis
Table 2 Primer and probe sequences used in the CDC and PAHO RT-qPCR assays
Name Sequence (5′ to 3′) Target Positiona Function Reference
ZIKV914prM TTGGTCATGATACTGCTGATTGC prM nt914–936 RT-qPCR forward primer Lanciotti et al. [17]
ZIKV990prMc CCTTCCACAAAGTCCCTATTGC prM nt990–969 RT-qPCR reverse primer Lanciotti et al., [17]
ZIKV965prMFAM FAM-CGGCATACAGCATCAGGTGCATAGGAG-TAMRA prM nt939–965 RT-qPCR forward probe Lanciotti et al., [17]
ZIKV1165E CCGCTGCCCAACACAAG E nt1165–1181 RT-qPCR forward primer Lanciottiet al., [17]
ZIKV1241Ec CCACTAACGTTCTTTTGCAGACAT E nt1241–1218 RT-qPCR reverse primer Lanciotti et al., [17]
ZIKV1216HEX HEX-AGCCTACCTTGACAAGCARTCAGACACTCAA-BHQ1 E nt1186–1216 RT-qPCR forward probe Lanciotti et al., [17]
ZIKV4513NS2B CTGTGGCATGAACCCAATAG NS2B nt4513–4532 RT-qPCR forward primer Waggoner and Pinsky, [43]
ZIKV4603NS2Bc ATCCCATAGAGCACCACTCC NS2B nt4603–4584 RT-qPCR reverse primer Waggoner and Pinsky, [43]
ZIKV4558cFAM FAM-CCACGCTCCAGCTGCAAAGG-TAMRA NS2B nt4558–4539 RT-qPCR probe Waggoner and Pinsky, [43]
aNucleotide position is based on ZIKV PRVABC59 strain (Puerto Rico, 2015), GenBank accession number KX087101.2
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determined that the limit of detection 95% (LOD95%)
of the ZIKV RT-iiPCR was 130 copies/μl of ZIKV
IVT RNA. Regarding the CDC and PAHO RT-qPCR
assays, the 100% detection endpoints were found at
10,000 IVT RNA copies/μl and 100 PFU/ml of
infectious TCF for the prM RT-qPCR assay, 100 IVT
RNA copies/μl and 10 PFU/ml of infectious TCF for
the E RT-qPCR assay, and 10 IVT RNA copies/μl
and 10 PFU/ml of infectious TCF for the NS2B
RT-qPCR assay, respectively (Tables 3 and 4).
LOD95% was estimated at 4102; 21; and 6 IVT RNA
copies/μl for the prM, E, and NS2B RT-qPCR assays,
respectively. Therefore, the overall analytical
sensitivity of the ZIKV RT-iiPCR was comparable
to that of the CDC E and PAHO NS2B RT-qPCR
assays in detecting viral RNA, while having a higher
performance when compared to that of the CDC
prM RT-qPCR assay.
(ii).Analytical specificity. The specificity and
pan-reactivity of the ZIKV CDC and PAHO RT-
qPCR and RT-iiPCR assays were evaluated using a
panel of reference viral RNA from different ZIKV
strains (African and Asian lineages) as well as other
flaviviruses and alphaviruses that frequently cause
similar clinical symptoms including DENV serotypes
1–4, WNV, YFV, and CHIKV (Table 1). The CDC
prM and PAHO NS2B RT-qPCR assays were able to
detect all ZIKV strains from the Asian lineage.
Table 3 Analytical sensitivity of ZIKV RT-qPCR and RT-iiPCR assays using ZIKV in vitro transcribed RNA
ZIKV prM RT-qPCR ZIKV E RT-qPCR ZIKV NS2B RT-qPCR ZIKV RT-iiPCR
ZIKV RNA copies/μl No. positive/No.
tested
Rate (%) No. positive/No.
tested
Rate (%) No. positive/No. tested Rate (%) No. positive/No. tested Rate (%)
107 6/6 100 6/6 100 6/6 100 6/6 100
106 6/6 100 6/6 100 6/6 100 6/6 100
105 6/6 100 6/6 100 6/6 100 6/6 100
104 6/6 100 6/6 100 6/6 100 6/6 100
103 3/6 50 6/6 100 6/6 100 6/6 100
102 1/6 17 6/6 100 6/6 100 5/6 83
10 0/6 0 5/6 83 6/6 100 5/6 83
1 0/6 0 1/6 17 1/6 17 1/6 17
0.1 0/6 0 0/6 0 0/6 0 0/6 0
PRVABC59, Puerto Rico 2015 strain (ATCC® VR-1843™)
Table 4 Analytical sensitivity of ZIKV RT-qPCR and RT-iiPCR assays using RNA derived from infectious tissue culture fluid (100–10−13)
ZIKV PRVABC59a
Dilutions ZIKV prM RT-qPCR (Ct value) ZIKV E RT-qPCR (Ct value) ZIKV NS2B RT-qPCR (Ct value) ZIKV RT-iiPCR
100 16.92 16.96 16.89 17.22 17.22 17.32 16.61 16.57 16.45 ND ND ND
10−1 19.34 19.42 19.36 19.41 19.34 19.43 18.87 18.90 18.86 ND ND ND
10−2 23.08 23.06 22.91 23.17 23.21 23.14 22.68 22.65 22.53 ND ND ND
10−3 26.02 26.08 26.05 26.18 26.18 26.12 25.50 25.54 25.52 ND ND ND
10−4 29.62 29.53 29.63 29.76 29.73 29.9 29.06 29.64 29.72 ND ND ND
10−5 32.66 32.50 32.73 33.13 32.94 32.90 32.29 32.01 31.99 Pos Pos Pos
10−6 Neg Neg Neg 36.89 36.61 36.26 36.94 35.98 36.71 Pos Pos Pos
10−7 Neg Neg Neg 40.64 Neg Neg Neg Neg Neg Pos Neg Pos
10−8 Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg
10−9 Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg
10−10 Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg
10−11 Neg Neg Neg Neg Neg Neg Neg Neg Neg ND ND ND
10−12 Neg Neg Neg Neg Neg Neg Neg Neg Neg ND ND ND
10−13 Neg Neg Neg Neg Neg Neg Neg Neg Neg ND ND ND
Detection endpoints (100%) are indicated in bold, and are equivalent to 100 PFU/ml for ZIKV prM RT-qPCR assay, and 10 PFU/ml for ZIKV E and NS2B RT-qPCR assays and
ZIKV RT-iiPCR assay. Neg negative, Pos positive, ND not determined; PRVABC59, Puerto Rico 2015 strain (ATCC® VR-1843™); a1x107 plaque forming units per ml (PFU/ml);
bold and italic, 100% detection end point
Carossino et al. BMC Infectious Diseases  (2017) 17:778 Page 7 of 15
However, the PAHO NS2B RT-qPCR assay did not
successfully amplify RNA derived from strains
belonging to the African lineage (MR 766 and IB H
30656) while the CDC prM RT-qPCR assay was able
to detect the IB H 30656 strain but not the MR 766
strain (Table 5). The CDC E RT-qPCR and the
RT-iiPCR assays successfully detected all ZIKV
strains from both lineages (Table 5). Moreover, the
RT-iiPCR detected ZIKV RNA (PRVABC59 and FLR
[Asian lineage], and MR766 [African lineage] strains)
derived from both infected mammalian (Vero) and
mosquito (C6/36 and AP-61) cell lines. All assays
were highly specific and did not detect any other
related flaviviruses or CHIKV (Table 5).
Performance evaluation of the RT-iiPCR using ZIKV-spiked
human samples
As a result of the lower analytical sensitivity of the CDC
prM RT-qPCR assay, the performance of the ZIKV RT-
iiPCR was evaluated and compared to the CDC E and
PAHO NS2B RT-qPCR assays as recently recommended
[43] using specimens (n = 481, including whole blood,
plasma, serum, semen, urine, and mosquitos) spiked with
different concentrations of ZIKV PRVABC59 strain. Nega-
tive controls were generated by the addition of non-infected
TCF to aliquots of the same clinical samples (mock-spiked).
(i).Whole blood.Whole blood samples derived from
20 healthy individuals were spiked with different
concentrations (106, 103, 102, 10, 1 and 0 [mock]
PFU/ml) of ZIKV PRVABC59 strain to simulate
varying degrees of viremia titers, giving a total of
100 ZIKV-spiked and 20 mock-spiked samples. The
combined use of the CDC and PAHO RT-qPCR
assays (CDC-PAHO RT-qPCR) detected 60/100
ZIKV-spiked samples while none of the mock-spiked
samples yielded positive results (0/20)
(Additional file 1: Table S1). All ZIKV-spiked
samples that yielded false negative results using the
CDC-PAHO RT-qPCR assays (40/100) contained
≤100 PFU/ml. Among these, eight samples yielded
inconclusive results with Ct > 38.5 for at least one of
the RT-qPCR assays, with a titer range within 10
(n = 6) to 1 (n = 2) PFU/ml of whole blood.
Detection rates per viral titer are shown in Table 6.
In contrast, the RT-iiPCR showed a higher detection
rate and identified 74/100 ZIKV-spiked samples
while none of the mock-spiked samples yielded
positive results (0/20). Similarly to the RT-qPCR
assays, those samples that yielded false negative
results (26/100) had viral titers ≤100 PFU/ml
(Table 6). The CDC-PAHO RT-qPCR and the RT-
iiPCR assays showed an agreement of 90% for this
sample type (k = 0.80 [CI 95%: 0.69–0.91]) (Table 7).
(ii).Plasma. Plasma samples derived from 20 healthy
individuals were spiked with different concentrations
of ZIKV PRVABC59 strain as previously indicated,
giving a total of 100 ZIKV-spiked and 20 mock-
spiked samples. The combined CDC-PAHO RT-
qPCR detected 74/100 ZIKV-spiked samples while
none of the mock-spiked samples yielded positive
results (0/20) (Additional file 1: Table S1). All
samples that yielded false negative results using the
CDC-PAHO RT-qPCR assays (26/100) contained
≤100 PFU/ml of ZIKV PRVABC59 strain. Among
these, five samples yielded inconclusive results with
Table 5 Inclusivity and exclusivity test panel used to compare the specificity of ZIKV RT-qPCR and RT-iiPCR assays
Virus Lineage ZIKV prM RT-qPCR
(Ct value)
ZIKV E RT-qPCR
(Ct value)
ZIKV NS2B RT-qPCR
(Ct value)
ZIKV RT-iiPCR
ZIKV MR 766 African Neg 18.85 Neg Pos
ZIKV IB H 30656 African 22.58 21.85 Neg Pos
ZIKV PRVABC59 Asian 16.94 17.27 17.81 Pos
ZIKV FLR Asian 18.89 18.97 20.94 Pos
ZIKV H/PAN/2015/CDC-259359 Asian 22.52 23.47 22.75 Pos
ZIKV H/PAN/2015/CDC-259249 Asian 26.85 27.24 26.27 Pos
ZIKV H/PAN/2015/CDC-259364 Asian 26.03 26.46 25.62 Pos
DENV serotype 1, Hawaii N/A Neg Neg Neg Neg
DENV serotype 2, New Guinea C N/A Neg Neg Neg Neg
DENV serotype 3, Philippines/H87/1956 N/A Neg Neg Neg Neg
DENV serotype 4, H241 N/A Neg Neg Neg Neg
YFV 17D N/A Neg Neg Neg Neg
WNV NY99 N/A Neg Neg Neg Neg
CHIKV H20235/STMARTIN/2013 N/A Neg Neg Neg Neg
Pos positive, Neg negative, N/A not applicable
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Ct > 38.5 for at least one of the RT-qPCR assays, all
of which had a titer of 1 PFU/ml (Table 6). In
contrast, the RT-iiPCR demonstrated a higher
detection rate and identified 86/100 ZIKV-spiked
samples while none of the mock-spiked samples
yielded positive results (0/20). Similarly to the RT-
qPCR assays, those samples that yielded false
negative results (14/100) had viral titers ≤100 PFU/
ml (Table 6). The agreement between the CDC-
PAHO RT-qPCR and the RT-iiPCR assays was 92%
(k = 0.82 [CI 95%: 0.71–0.93]) (Table 7), higher than
that observed with whole blood samples.
(iii). Serum. Serum samples derived from 20 healthy
individuals were spiked with different
concentrations of ZIKV PRVABC59 strain as
previously indicated, giving a total of 100 ZIKV-
spiked and 20 mock-spiked samples. The
combined CDC-PAHO RT-qPCR detected
78/100 ZIKV-spiked samples while none of the
mock-spiked samples yielded positive results
(0/20) (Additional file 1: Table S1). All samples
that yielded false negative results using the
CDC-PAHO RT-qPCR assays (22/100) were
spiked with ≤10 PFU/ml of ZIKV PRVABC59
strain (Table 6), which demonstrated a lower
detection limit compared to other blood-derived
specimens (i.e. whole blood and plasma). Among
these, nine samples yielded inconclusive results
with Ct > 38.5 for at least one of the RT-qPCR
assays, with 7/9 having a titer of 1 PFU/ml and
2/9 having a titer of 10 PFU/ml. In contrast, the
RT-iiPCR showed a higher detection rate and
identified 90/100 ZIKV-spiked samples while none
of the mock-spiked samples yielded positive
results (0/20). Those samples that yielded false
negative results (10/100) had viral titers of 1 PFU/ml
(Table 6). The highest level of agreement between
assays was observed for this sample type among other
blood-derived specimens (95%; k = 0.86 [CI 95%:
0.76–0.97]) (Table 7). Even though the RT-iiPCR had
a higher detection rate than the RT-qPCR assays, both
assays consistently detected viral RNA in samples con-
taining as low as 100 PFU/ml of virus.
(iv). Semen. Since it has been recently demonstrated
that ZIKV can be sexually transmitted from infected
individuals, we assessed the performance of the
ZIKV RT-iiPCR in spiked semen samples. Each of a
total of 4 pooled semen samples (semen from three
individuals per pool [total of 12 semen samples])
were spiked with 106, 103, 102, 10, 1 and 0 (mock)
PFU/ml of ZIKV PRVABC59 strain (n = 24). The
CDC-PAHO RT-qPCR detected 15/20 ZIKV-spiked
samples while none of the negative samples yielded
positive results (0/4) (Additional file 1: Table S1).
One out of the 5 false negative results obtained using
the CDC-PAHO RT-qPCR assays contained a viral
titer of 10 PFU/ml, while the other samples that
yielded negative results had viral titers of 1 PFU/ml
of semen (Table 6). The RT-iiPCR detected 17/20
positive samples and 0/4 negative samples. The three
ZIKV-spiked samples that were undetectable had
viral titers of 1 PFU/ml (Table 6). In
summary, the agreement between the two assays
was 92% (k = 0.81 [CI 95%: 0.57–1]) (Table 7).
Table 6 Detection rates per assay according to the specimen’s
viral titer and sample type
Sample
type
Viral titer
(PFU/ml)
RT-iiPCR
No. positive/No. tested
CDC-PAHO RT-qPCR
No. positive/No. testeda
Whole
blood
1 4/20 0/20 (2)
10 11/20 3/20 (6)
102 19/20 17/20
103 20/20 20/20
106 20/20 20/20
Plasma 1 9/20 1/20 (5)
10 18/20 14/20
102 19/20 19/20
103 20/20 20/20
106 20/20 20/20
Serum 1 10/20 1/20 (7)
10 20/20 17/20 (2)
102 20/20 20/20
103 20/20 20/20
106 20/20 20/20
Semen 1 1/4 0/4
10 4/4 3/4
102 4/4 4/4
103 4/4 4/4
106 4/4 4/4
Urine 1 1/20 0/20
10 12/20 1/20 (5)
102 20/20 16/20 (3)
103 20/20 20/20
106 20/20 20/20
Mosquito
pools
1 0/1 0/1
10 1/1 1/1
102 1/1 1/1
103 1/1 1/1
104 1/1 1/1
106 1/1 1/1
aNumber between parentheses indicates the number of inconclusive
results (Ct > 38.5)
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(v).Urine. Urine samples derived from 20 healthy
individuals were spiked with different
concentrations of ZIKV PRVABC59 strain as
previously indicated, giving a total of 100 ZIKV-
spiked and 20 mock-spiked samples. The
combined CDC-PAHO RT-qPCR detected 57/100
ZIKV-spiked samples while none of the mock-
spiked samples yielded positive results (0/20)
(Additional file 1: Table S1). All samples that
yielded false negative results (43/100) were spiked
with ≤100 PFU/ml of ZIKV PRVABC59 strain
(Table 6). Among the eight samples that yielded
inconclusive results (Ct > 38.5 for at least one of
the RT-qPCR assays), 5/8 and 3/8 had a titer of
10 PFU/ml and 100 PFU/ml, respectively. In
contrast, the RT-iiPCR showed a higher detection
rate and identified 73/100 ZIKV-spiked samples
while none of the mock-spiked samples yielded
positive results (0/20). Those samples that yielded
false negative results (27/100) had viral titers ≤10
PFU/ml (Table 6). The level of agreement between
assays for this sample type was 90% (k = 0.79
[CI 95%: 0.67-0.89]) (Table 7).
Performance evaluation of the RT-iiPCR using ZIKV-spiked
mosquito pools
The performance of the PON ZIKV RT-iiPCR was
also evaluated in ZIKV-spiked mosquito pool speci-
mens to assess its suitability as a rapid surveillance
test in the vector population. Six mosquito pools (A.
albopictus, n = 15 per pool) spiked with ZIKV
PRVABC59 strain at concentrations ranging from 106
to 1 PFU/ml of mosquito pool homogenate (equiva-
lent to 6 × 104 – 0.06 PFU/mosquito) and a mock-
spiked A. albopictus pool (n = 15) were evaluated.
Both the combined CDC-PAHO RT-qPCR and RT-
iiPCR correctly identified 5/7 ZIKV- (106 − 10 PFU/
ml) and mock-spiked mosquito pools, with the excep-
tion of that containing 1 PFU/ml (Table 6), indicating
100% agreement between assays (Table 7).
Overall performance comparison between ZIKV RT-iiPCR
and the reference CDC and PAHO ZIKV RT-qPCR assays
Analysis of a total of 481 spiked and mock-spiked whole
blood, plasma, serum, semen, urine, and mosquito pool
specimens (excluding samples that yielded inconclusive
RT-qPCR results) determined an overall agreement of
Table 7 Agreement between the RT-iiPCR and RT-qPCR assays for detection of ZIKV RNA in diverse spiked specimens
Specimen type RT-iiPCR CDC-PAHO RT-qPCRa Agreement (k, CI95%)b
Positive Negative Total
Overall performance Positive 288 38 326 92% (0.83 [0.77–0.88])
Negative 1 154 155
Total 289 192 481
Whole blood Positive 60 11 71 90% (0.80 [0.69–0.91])
Negative 0 41 41
Total 60 52 112
Plasma Positive 74 9 83 92% (0.82 [0.71–0.93])
Negative 0 32 32
Total 74 41 115
Serum Positive 78 6 84 95% (0.86 [0.76–0.97])
Negative 0 27 27
Total 78 33 111
Semen Positive 15 2 17 92% (0.81 [0.57–1])
Negative 0 7 7
Total 15 9 24
Urine Positive 56 10 66 90% (0.79 [0.67–0.89])
Negative 1 45 46
Total 57 55 112
Mosquito pools Positive 5 0 5 100% (1)
Negative 0 2 2
Total 5 2 7
aSamples that yielded inconclusive results (Ct > 38.5) were not included in the analysis. bThe Kappa statistic and 95% confidence interval is shown within brackets
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92% (k = 0.83 [CI 95%: 0.77–0.88]) between the ZIKV
RT-iiPCR and the CDC and PAHO ZIKV RT-qPCR
assays (Table 7) along with no statistical differences
in their specificity (McNemar’s test, p-value > 0.01).
Even though there is no consensus gold standard test
for the diagnosis of ZIKV infection in different clin-
ical specimens, contingency analysis of ZIKV- and
mock-spiked specimens demonstrated that the ZIKV
RT-iiPCR had a higher sensitivity than the composite
results obtained from the CDC-PAHO RT-qPCR as-
says for the detection of viral RNA in whole blood,
plasma, and urine samples (McNemar’s test, p-value <
0.01). In contrast, no statistical differences in sensitiv-
ity were observed for serum, semen, and mosquito
pool specimens between assays.
Discussion
ZIKV has caused a major pandemic in the Americas
during 2015–2016, with serious repercussions to the
healthcare system in Brazil as well as other Caribbean
countries [1, 4–8, 10, 11, 38, 42, 71]. In addition to its
vector-mediated transmission, it has been demonstrated
that ZIKV can be shed in the semen of infected male
patients and be effectively transmitted during sexual
intercourse [27–31, 72–76]. Furthermore, it also poses a
significant threat to the blood bank network [33–36, 77].
Even though there are two CDC-validated and one
PAHO-validated RT-qPCR assays for molecular diagno-
sis of ZIKV infection [17, 43], these are not suitable for
use within clinical settings in rural areas or may not be
available in areas with limited resources including devel-
oping countries where ZIKV is spreading at an acceler-
ated rate. This disease, among other mosquito-borne
infections, adds impetus to the development of accurate,
rapid, inexpensive, and on-site detection methodologies
(i.e. PON) that can aid in the clinical management of
affected patients, disease surveillance, and control of epi-
demics in vulnerable areas and also ensure rapid testing
of blood and blood products in blood banks. Here, we
report the development and evaluation of a PON
molecular detection test (RT-iiPCR assay) for the detec-
tion of ZIKV RNA in diverse human specimens that are
likely to be encountered under field conditions. Further-
more, we determined that this assay is appropriate for
detection of ZIKV RNA in homogenized mosquito
pools, demonstrating its potential utility for monitoring
viral prevalence in vector populations. This assay is
based on the iiPCR technology [55], and it is designed
for use in conjunction with a fully field-deployable de-
vice (POCKIT™ Nucleic Acid Analyzer, GeneReach USA)
that allows rapid amplification and detection of viral
nucleic acids (~1.5 h from sample to result, including
nucleic acid extraction time [Fig. 1]). A number of
iiPCR-based assays have been developed for detection of
human and animal pathogens [56, 57, 59–70] with two
of the most recent additions being directed against all
serotypes of DENV and MERS-CoV [56, 58]. The sensi-
tivity and specificity of all iiPCR-based assays have dem-
onstrated to be comparable with other diagnostic
methods currently in use (e.g. RT-qPCR, nested PCR,
virus isolation). However, RT-iiPCR offers several advan-
tages over conventional molecular-based assays (e.g. RT-
qPCR assays) including lyophilized reagents that can be
transported at ambient temperature, ease of reaction
setup, automated detection and simple result interpret-
ation in the form of “+” (positive result) or “-” (negative
result), and rapid results (Fig. 1).
The POCKIT™ system can be combined with field-
deployable manual or automatic nucleic acid extrac-
tion systems (PetNAD™ Nucleic Acid Co-prep Kit or
taco™ mini Nucleic Acid automated extraction system
[taco™ mini], GeneReach USA) or other column-based
extraction systems of choice. Accordingly, a taco™
mini (30 × 26.5 × 26 cm, W x D x H, 5 kg) and a
POCKIT™ device (31 × 26 × 15 cm, W x D x H,
2.1 kg) have been combined for field applications
(POCKIT™ Combo), and can be powered by a car or re-
chargeable battery. The POCKIT™ Combo has been ac-
cepted as a mobile PCR tool in the management of animal
health. Also, a hand-held model, POCKIT™ Micro Plus
(6.3 × 15.2 × 5.0 cm, W x D x H; 0.3 kg; GeneReach USA)
has been developed for field applications. Recently, feasi-
bility of the combination of POCKIT™ Micro Plus and the
automatic taco™ mini was demonstrated in a field test car-
ried out in Vietnam for monitoring avian influenza A vi-
ruses in poultry markets. Test results using a influenza A
RT-iiPCR reagent set were comparable to those of an RT-
qPCR in a central laboratory (unpublished data). Further-
more, we have clearly demonstrated that this platform can
be used for dengue and MERS-CoV diagnosis in human
clinical samples [56, 58]. Thus, the POCKIT™ system plus
the automatic bead-based taco™ mini is potentially suitable
for use as a PON tool for ZIKV detection in clinical
specimens.
To date, three other PON assays based on the use of
either biomolecular sensors/CRISPR-based technology,
reverse transcription loop-mediated isothermal amplifi-
cation (RT-LAMP), or reverse transcription strand inva-
sion based amplification (RT-SIBA) technologies have
been described for detection of ZIKV RNA [52–54].
While these methods provide rapid, on-site results, they
offer a limited sensitivity [52], limited specificity [54], or
have not been compared to the CDC or PAHO-validated
RT-qPCR of routine use in diagnostic laboratories
[53]. In addition, their performance has not been
evaluated in a large set of specimens. Instead, the
ZIKV RT-iiPCR assay involves the use of a technology
specifically developed for field application and which
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has already been validated for detection of several
major pathogens in clinical samples, and is based on
the TaqMan® chemistry which is less likely to yield
false positive results.
Detection of ZIKV RNA can be achieved in several
sample types derived from infected individuals includ-
ing blood–derived samples (whole blood, plasma,
serum), other body fluids (semen, urine, saliva, vaginal
secretions), and cytological specimens [43, 78–80]. The
period of time during which viral RNA is detectable
varies depending on the sample type as well as individ-
ual variation, ranging from a short (transient viremia)
to a prolonged time post-infection in the case of other
body fluids such as urine, semen, and saliva. Even
though detection of ZIKV RNA during the viremic
period is usually possible within the first week after
disease onset [6, 81], a recent study has estimated that
ZIKV RNA loss occurs at a median of 14 days in serum
(95th percentile up to 54 days), 8 days in urine (95th
percentile up to 39 days), and 34 days in semen (95th
percentile up to 81 dpi) in infected humans [79].
However, ZIKV has been detected for as long as
6 months in semen of some individuals [76]. Viral titers
are also variable depending on the clinical specimen
tested, days post-infection, and other factors. Viremia ti-
ters can range from 2 to 106 PFU/ml (~9 × 102–7.3 × 105
viral RNA copies/ml) of blood [17, 46] while urine titers
seem to be frequently within the 10 to 103 PFU/ml range
(~4.3 × 102–2.5 × 105 viral RNA copies/ml) [82]. Inter-
estingly, seminal shedding occurs at very high viral
loads (2.9 × 108–1.2 × 103 viral RNA copies/ml) [75]. In
this study, specimens were spiked over a range of viral
concentrations according to the estimated viral titers
observed in ZIKV naturally infected individuals. Since
the RT-iiPCR, CDC E, and PAHO NS2B assays showed
an equal 100% detection rate (10 PFU/ml) and strong
agreement between each other (k = 0.83), it is expected
that the RT-iiPCR would have a similar clinical
performance as the reference RT-qPCR assays and be
suitable for detecting clinical specimens with at least a
viral titer of 10 PFU/ml, while lower viral titers as those
observed during late viremia may offer challenges and,
consequently, the use of other tests may be more
suitable at that stage of infection (i.e. serological tests).
Even though we have extensively evaluated this assay
using spiked human specimens and mosquitoes, testing
of clinical specimens derived from infected individuals
and mosquitoes is required to further confirm the
performance of this new PON assay under field
conditions.
In this study, the ZIKV-specific RT-iiPCR assay dem-
onstrated a comparable analytical sensitivity and speci-
ficity to reference RT-qPCR assays that have been
validated by CDC and PAHO for diagnosis of this
flaviviral infection in humans. The ZIKV RT-iiPCR tar-
gets a conserved region within the E gene and while it
is capable of detecting ZIKV strains from both Asian
and African lineages, it showed no reactivity with
genomic RNA from other flaviviruses or CHIKV.
Regarding the assay’s performance in spiked specimens,
the RT-iiPCR demonstrated a substantial level of
agreement with the reference RT-qPCR assays (92%, k
= 0.83). The best performance for both the RT-iiPCR
and the reference RT-qPCR assays was observed for
plasma, serum, semen, and mosquito pools, with levels
of agreement higher than 90%. In the case of ZIKV-
spiked whole blood, plasma, and urine, false negative
results were frequently observed for both the RT-iiPCR
and reference RT-qPCR assays in those samples con-
taining ≤100 PFU/ml of ZIKV. Such limitations in the
detection of viral RNA in these samples were consistent
with results from previous studies [46, 48, 83]; and may
be associated with sample volume, the presence of PCR
inhibitors [84–86], or extremely low concentrations of
target RNA. Even though limited sample volumes may
have an impact on the assay’s performance, the use of a
reduced volume of semen samples in this study (100 μl)
did not appear to have detrimental effects on the
results. Although this study suggests that serum may be
a more suitable sample for PCR-based testing of ZIKV
than whole blood or plasma, this needs to be further
evaluated using clinical samples from naturally infected
patients.
Conclusions
In conclusion, the ZIKV RT-iiPCR reagent set provides
comparable performance to the reference CDC and
PAHO RT-qPCR assays currently in use for diagnosis of
ZIKV in a variety of spiked specimen types including
mosquitoes. Nonetheless, further evaluation of its
performance in clinical samples derived from infected
patients is warranted. In contrast to the RT-qPCR assays,
the RT-iiPCR assay is fully deployable under field condi-
tions and, thus, can be used as a PON assay in remote,
resource-deprived areas to provide rapid results (~1.5 h
turnaround time from sample to result) at relatively low
costs (< 10 USD per RT-iiPCR test vs. ≥ 20 USD per
RT-qPCR test) and with the use of reagents that are
stable at room temperature for two years without com-
promising the assay’s performance. Therefore, the ZIKV
RT-iiPCR could provide a highly effective PON assay
that would enhance disease management, screening of
blood bank supplies, and viral surveillance in human or
insect populations with an improvement of the quality
of the health care system of major significance particu-
larly in remote or low-infrastructure areas within
developing countries.
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